Marketwire -- Regensburg, August 13, 2008 - GENEART AG, the global leader in gene synthesis and specialist in the field of Synthetic Biology, is operating in a strong running market environment with its gene synthesis core business. The demand for optimized synthetic genes in research as well as in the pharmaceutical and biotechnology industries grows steadily. Supported by the market development, the GENEART AG was again able to significantly increase its net sales and operating result (EBIT) in the 1st half of 2008 while expanding its leading market position.
